The immunogenetics of measles immunity
This project focuses on genes that influence and determine the human immune response to the measles vaccine. This knowledge allows for a better understanding of how measles immunity develops after vaccination and why a range of immune responses occurs.
Innate immune function in older adults
This project, funded by the Robert and Arlene Kogod Center on Aging at Mayo Clinic, focuses on the interaction between influenza vaccination and inflammasomes and the impact of senescence — the condition or process of deterioration with age — on this interaction, along with the subsequent adaptive immune response to the influenza virus.
Systems biology assessment of influenza A/H1N1 vaccination in an Indian cohort
This project, done in collaboration with the Rajiv Gandhi Centre for Biotechnology in Thiruvananthapuram, Kerala, India, focuses on developing innovative immune profile signatures that explain and predict interindividual variations in immune responses to influenza A/H1N1 vaccines specifically and viral vaccines generally. Another important goal is to compare and contrast immunological and transcriptomic profiles after influenza vaccination in the Caucasian and Indian populations. The use of these two populations allows comparison of subjects with preexisting immunity due to natural infections versus immunity due to vaccination.
The effect of influenza A vaccination on miRNA expression and immune outcome
The goal of this study is to identify key miRNAs involved in influenza vaccine responses, as well as the genes and pathways targeted by these specific miRNAs. These data may provide the biomarkers that can predict immune response and serve as correlates of protection. The group's findings serve as a foundation for more detailed and mechanistic studies into the functional relevance of the identified miRNAs.
Translating the discovery of immunogenic measles peptides into a candidate vaccine
The Vaccine Research Group has identified 13 naturally processed HLA-DRB1*03-restricted measles peptides. The current live-virus measles vaccine is highly effective and widely used; however, outbreaks among vaccinated individuals continue to occur. Difficulties encountered with the current vaccine include preexisting maternal antibodies that suppress response to the vaccine, cold chain requirements for vaccine viability, contraindicated use in immunocompromised individuals and the requirement for trained health care providers to administer the vaccine. The group's ability to identify critical measles epitopes is a significant step in developing a safe and effective peptide-based measles vaccine that circumvents these issues related to vaccine failure.
See Vaccine Research Group publications related to measles and peptides.
See all publications by Mayo Clinic authors related to measles.
Learn about diagnosis and treatment of measles.